- Home
- STEC vs FEMY Comparison
STEC vs FEMY Comparison
Compare STEC & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- FEMY
- Stock Information
- Founded
- STEC 2006
- FEMY 2004
- Country
- STEC Hong Kong
- FEMY United States
- Employees
- STEC N/A
- FEMY N/A
- Industry
- STEC
- FEMY Medical/Dental Instruments
- Sector
- STEC
- FEMY Health Care
- Exchange
- STEC NYSE
- FEMY Nasdaq
- Market Cap
- STEC 29.7M
- FEMY 31.9M
- IPO Year
- STEC 2021
- FEMY 2021
- Fundamental
- Price
- STEC $0.80
- FEMY $0.91
- Analyst Decision
- STEC
- FEMY Strong Buy
- Analyst Count
- STEC 0
- FEMY 3
- Target Price
- STEC N/A
- FEMY $8.67
- AVG Volume (30 Days)
- STEC 14.1K
- FEMY 282.0K
- Earning Date
- STEC 07-22-2025
- FEMY 08-07-2025
- Dividend Yield
- STEC N/A
- FEMY N/A
- EPS Growth
- STEC N/A
- FEMY N/A
- EPS
- STEC N/A
- FEMY N/A
- Revenue
- STEC $10,672,000.00
- FEMY $1,699,232.00
- Revenue This Year
- STEC $9,392.20
- FEMY $231.84
- Revenue Next Year
- STEC N/A
- FEMY $245.28
- P/E Ratio
- STEC N/A
- FEMY N/A
- Revenue Growth
- STEC N/A
- FEMY 61.97
- 52 Week Low
- STEC $0.20
- FEMY $0.69
- 52 Week High
- STEC $3.25
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- STEC 38.10
- FEMY 50.88
- Support Level
- STEC $0.81
- FEMY $0.90
- Resistance Level
- STEC $0.88
- FEMY $0.99
- Average True Range (ATR)
- STEC 0.07
- FEMY 0.07
- MACD
- STEC -0.00
- FEMY 0.01
- Stochastic Oscillator
- STEC 15.97
- FEMY 39.48
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.